•  
  •  
 

Abstract

ABSTRACT: BACKGROUND: Second-generation sulfonylureas (SU) are efficacious, generally well-tolerated, cost-effective options for the medical management of diabetes. Glimepiride which is sometimes classified as a third-generation has benefits over other in that it has a considerably lower binding affinity for the B-cell receptor, result in a modulation of insulin release, and a decreased potential for inducing hypoglycemia. OBJECTIVE: This study was designed to evaluate the outcome of using glimepiride and glibenclamide in type 2 diabetic patients. PATIENTS AND METHODS: A single blinded randomized clinical trial was adopted, in which 64 already diagnosed diabetic patients (regardless disease duration) were recruited from Al-Yarmouk hospital, and randomized into two groups; 1 INTRODUCTION: Sulfonylureas have been used for type 2 diabetes for over 50 years (1) . They act by stimulating insulin release from the beta cells of the pancreas. They bind to sulfonylurea receptors found on the surface of pancreatic β-cells and this interaction leads to closure of K -ATP channels, the cell membrane is depolarized and insulin is released (2) st group (32 patients) treated with 5 mg glibenclamide, and 2 group (32 patients) treated with 3 mg glimepride for 4 months. Fasting blood sugar (FBS), glycosylated hemoglobin (HbA1c) level, triglyceride, cholesterol, serum electrolyte (Na, K, Ca) level and pulse rate were measured at zero time (first visit)and at the end of the study (after 4 months). RESULTS: The result showed that both Fasting blood sugar, glycosylated hemoglobin, serum total cholesterol, triglyceride levels were decreased significantly in both treatment group but with greater reduction in group 2, serum electrolytes were not significantly affected, except calcium level which was increased significantly in glimepiride group only. Moreover, no significant effect observed regarding pulse rate compared to pretreatment period. CONCLUSION: Glimepride provide more potent glycemic control and better lipid profile compared to glibenclamide in type 2 diabetic patients

Download

Share

COinS